Plain-English translation of NCT05436223 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called CD19 CAR-T therapy, which uses your own immune cells specially trained to fight lymphoma cancer cells. Researchers will collect some of your white blood cells, reprogram them in the laboratory to recognize and attack cancer, and then give them back to you as an infusion. This is a Phase 2 study, meaning the treatment has shown early promise and researchers now want to see if it works well and is safe in a larger group of patients.
Some people with aggressive B-cell lymphoma don't respond to standard chemotherapy or surgery, or their cancer comes back after treatment. This medication offers a new approach by training the body's own immune system to fight the cancer, which may help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You will be hospitalized to undergo this treatment. First, doctors will collect some of your white blood cells through a procedure called leukapheresis. Your cells will be sent to the laboratory to be reprogrammed, which takes time. Once ready, you will receive a single infusion of the treated cells after receiving a short course of chemotherapy to prepare your body. You will then be closely monitored in the hospital and during follow-up visits to see how well the treatment works and to watch for any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China